Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates.
Daniel D. Von Hoff
Consultant or Advisory Role - Celgene (U)
Honoraria - Celgene
Research Funding - Celgene
Thomas J. Ervin
Research Funding - Celgene
Francis P. Arena
Research Funding - Celgene
E. Gabriela Chiorean
Research Funding - Celgene
Jeffrey R. Infante
No relevant relationships to disclose
Malcolm J. Moore
Consultant or Advisory Role - Celgene
Research Funding - Celgene
Thomas E. Seay
Research Funding - Celgene
Sergei Tjulandin
Research Funding - Celgene
Wen Wee Ma
Research Funding - Celgene
Mansoor N. Saleh
Research Funding - Celgene
Marion Harris
No relevant relationships to disclose
Michele Reni
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Research Funding - Celgene
Ramesh K. Ramanathan
Consultant or Advisory Role - Celgene (U)
Honoraria - Abraxis BioScience
Research Funding - Celgene
Josep Tabernero
Consultant or Advisory Role - Celgene
Manuel Hidalgo
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Research Funding - Celgene
Eric Van Cutsem
Research Funding - Celgene
David Goldstein
Consultant or Advisory Role - Celgene (U)
Research Funding - Celgene
Xinyu Wei
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Jose Luis Iglesias
Employment or Leadership Position - Bionomics
Stock Ownership - Celgene
Markus Frederic Renschler
Employment or Leadership Position - Celgene
Stock Ownership - Celgene (I)